Bayer raises its brand profile
- Details
- Category: Bayer
The Bayer Group plans to greatly strengthen the "Bayer" umbrella brand and steadily reduce the number of its other corporate brands.
KOMBIGLYZE™ XR tablets approved in the US
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults.
Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with Enbrel(R) (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care.
Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the2010 Scrip Awards ceremony Nov. 4 in London.
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate
- Details
- Category: Novartis
New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of geographically and genetically diverse meningococcal serogroup B (MenB) strains.
Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia.
Lilly CEO Calls for a 'Wave of Invention' to Reduce the Toll of Diabetes
- Details
- Category: Eli Lilly and Company
In a speech to the Cleveland Clinic Medical Innovation Summit, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY) described the "paradox of progress" against diabetes, noting that "for all our progress in treating diabetes, our ultimate goal seems as far away as ever."
More Pharma News ...
- Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
- Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound
- Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries
- Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
- Nycomed to accelerate expansion in China
- Novartis drug Afinitor® approved by FDA
- GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal